Page last updated: 2024-10-15

bis(molybdopterin guanine dinucleotide)molybdenum

Description

bis(molybdopterin guanine dinucleotide)molybdenum: cofactor of dimethylsulfoxide reductase; isolated from Rhodobacter capsulatus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bis(molybdopterin guanine dinucleotide)molybdenum(4-) : An organophosphate oxoanion arising from deprotonation of the four diphosphate OH groups of bis(molybdopterin guanine dinucleotide)molybdenum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID136262913
CHEBI ID71312
MeSH IDM0278499

Synonyms (4)

Synonym
bis(molybdopterin guanine dinucleotide)molybdenum
bis{5'-o-[{[{[(5ar,8r,9ar)-2-amino-4-oxo-6,7-di(sulfanyl-kappas)-3,5,5a,8,9a,10-hexahydro-4h-pyrano[3,2-g]pteridin-8-yl]methoxy}(hydroxy)phosphoryl]oxy}(hydroxy)phosphoryl]guanosinato(4-)}molybdate(4-)
CHEBI:71312
bis(molybdopterin guanine dinucleotide)molybdenum(4-)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organophosphate oxoanionAn organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]